Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections

NCT03331445 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

13

Enrollment

INDUSTRY

Sponsor class

Stopped Covid Incidence too low and Funding Completed

Conditions

Respiratory Tract Infections
Corona Virus Infection

Interventions

DRUG: Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation

Sponsor

Chris Miller

Collaborators

[object Object]